Clinical Trial News and Research

RSS

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix® for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013.

7 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

...

6 Sep 2013

Cellular Biomedicine Group reports interim results of Phase I/IIa clinical trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc. today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis, which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.

6 Sep 2013

New research initiative to focus on ultrasound therapy

The Focused Ultrasound Foundation and Philips have entered into an innovative public-private collaboration with The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.

6 Sep 2013

Greenwich Hospital's new radiation oncology therapy gives renewed hope to HRPC patients

At the end of July, Greenwich became the only hospital in New York City, Westchester and Fairfield counties to offer Xofigo, commonly referred to as Radium 223, a new radiation oncology therapy that is giving renewed hope to patients with stage 4 hormone-refractory prostate cancer.

6 Sep 2013

Biomarker strategy in suspected ACS patients has potential to change clinical practice

An emergency department strategy that uses two biomarkers to triage patients with suspected acute coronary syndrome (ACS) can increase the rate of early, safe hospital discharge, according to results of the Biomarkers in Cardiology 8 (BIC-8) trial.

5 Sep 2013

Experimental agent fails to increase HDL levels, reveals new study

The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

5 Sep 2013

TASTE trial questions the usefulness of thrombus aspiration after heart attack

Aspiration of the blood clot or "thrombus" that causes a heart attack before re-opening a patient's artery with a balloon catheter does not improve survival compared to performing balloon dilation and stenting alone according to the results of the Thrombus Aspiration in ST- Elevation myocardial infarction in Scandinavia (TASTE) trial.

5 Sep 2013

Study finds similar antibody levels among 4 PCV13 immunization schedules

The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes, according to a study in the September 4 issue of JAMA.

5 Sep 2013

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

A new -13 million partnership to accelerate cancer-focused drug discovery in Northern Ireland has been launched by Enterprise Minister Arlene Foster MLA.

5 Sep 2013

New laser-based technology may make brain tumor surgery more accurate

A new laser-based technology may make brain tumor surgery much more accurate, allowing surgeons to tell cancer tissue from normal brain at the microscopic level while they are operating, and avoid leaving behind cells that could spawn a new tumor.

5 Sep 2013

Research findings raise hope for new heart therapies

Many people who survive a heart attack find themselves back in the hospital with a failing heart just years later. And the outcome often is unfavorable, owing to limited treatment options. But scientists at Temple University School of Medicine's Cardiovascular Research Center recently found hope in an unlikely source - stem cells in cortical, or compact, bone.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Removing of carotid body appears to be effective for high blood pressure

Removing one of the tiniest organs in the body has shown to provide effective treatment for high blood pressure. The discovery, made by University of Bristol researchers and published in Nature Communications, could revolutionise treatment of the world's biggest silent killer.

4 Sep 2013

Scientists identify new drugs that have potential to slow down progression of Parkinson's

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

4 Sep 2013

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

4 Sep 2013

Clinical Trial News and Research

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

New Sponge-Based Therapeutic Cancer Vaccine Begins Human Clinicals

Cellular Biomedicine Group reports interim results of Phase I/IIa clinical trial for Knee Osteoarthritis

New research initiative to focus on ultrasound therapy

Greenwich Hospital's new radiation oncology therapy gives renewed hope to HRPC patients

Biomarker strategy in suspected ACS patients has potential to change clinical practice

Experimental agent fails to increase HDL levels, reveals new study

TASTE trial questions the usefulness of thrombus aspiration after heart attack

Study finds similar antibody levels among 4 PCV13 immunization schedules

£13M partnership to accelerate cancer-focused drug discovery launched by Queen's and Almac Discovery

New laser-based technology may make brain tumor surgery more accurate

Research findings raise hope for new heart therapies

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Removing of carotid body appears to be effective for high blood pressure

Scientists identify new drugs that have potential to slow down progression of Parkinson's

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer